Horner syndrome is typically described by the classic triad of blepharoptosis, miosis, and anhydrosis resulting from disruption along the oculosympathetic pathway. Because of the complex and extensive course of this pathway, there are a large number of causes of Horner syndrome ranging from benign to life-threatening diseases. This review article aims to provide a practical approach to investigation and management, including evaluation of the more recent use of apraclonidine for pharmacological testing.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/APO.0b013e318256009d | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!